The present invention relates to a combinations of direct AMPK activators with indirect AMPK activators for use in activating AMPK. In particular, combinations of benzocoumarins of formula I which are direct AMPK activators with urolithins of formula VII which are indirect AMPK activators.

The present invention relates to a combinations of direct AMPK activators with indirect AMPK activators for use in activating AMPK. In particular, combinations of benzocoumarins of formula I which are direct AMPK activators with urolithins of formula VII which are indirect AMPK activators.

The present invention provides a pharmaceutical composition which comprises: (a) an HMG-CoA reductase inhibitor; and (b) cholesterol or a pharmaceutically acceptable precursor thereof; for use in treating psoriasis.

The present invention provides a pharmaceutical composition which comprises: (a) an HMG-CoA reductase inhibitor; and (b) cholesterol or a pharmaceutically acceptable precursor thereof; for use in treating psoriasis.

The present invention provides a pharmaceutical composition which comprises: (a) an HMG-CoA reductase inhibitor; and (b) cholesterol or a pharmaceutically acceptable precursor thereof; for use in treating psoriasis.

A nutritional supplement composition that extends the utility of the prior art methods to include enhanced utility for bone health via modulation of the RANK, RANKL, NFKB signaling system and incorporates unrelated, unforeseen benefits on brain health based on the beneficial impact of the same signaling system on brain health thus preventing loss of neurological function and/or normalizing impaired or deteriorating neurological function in humans based on: (1) mitigation of the adverse impact of dysregulated acid-base balance, (2) dysregulation of prostaglandin physiology, (3) abnormalities in RANK, RANKL, NFKB physiology. reversing elevated NFKB, RANK, RANKL signaling. The nutrients that are ideal for the desired result are Honokiol, Magnolol, Beta-caryophyllene, Palmitoylethanolamide, Hesperidin, Schisandrin, Ferulic Acid, Beta-carotene, Lutein, Lycopene, Sulforaphane, and Ellagic Acid.

A nutritional supplement composition that extends the utility of the prior art methods to include enhanced utility for bone health via modulation of the RANK, RANKL, NFKB signaling system and incorporates unrelated, unforeseen benefits on brain health based on the beneficial impact of the same signaling system on brain health thus preventing loss of neurological function and/or normalizing impaired or deteriorating neurological function in humans based on: (1) mitigation of the adverse impact of dysregulated acid-base balance, (2) dysregulation of prostaglandin physiology, (3) abnormalities in RANK, RANKL, NFKB physiology. reversing elevated NFKB, RANK, RANKL signaling. The nutrients that are ideal for the desired result are Honokiol, Magnolol, Beta-caryophyllene, Palmitoylethanolamide, Hesperidin, Schisandrin, Ferulic Acid, Beta-carotene, Lutein, Lycopene, Sulforaphane, and Ellagic Acid.

The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.

The present invention concerns a pharmaceutical composition comprising a compound of Formula I for use in the treatment and/or prevention of microbial infections. Furthermore, the present invention concerns a method for prevention and/or reduction of biofilm formation.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.